Compare · BIOA vs NVO
BIOA vs NVO
Side-by-side comparison of BioAge Labs Inc. (BIOA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIOA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $219.94B, about 237.0x BIOA ($928.2M).
- Over the past year, BIOA is up 359.5% and NVO is down 28.0% - BIOA leads by 387.5 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 1 for BIOA).
- NVO has more recent analyst coverage (25 ratings vs 15 for BIOA).
- Company
- BioAge Labs Inc.
- Novo Nordisk A/S
- Price
- $20.84-4.40%
- $49.68+1.85%
- Market cap
- $928.2M
- $219.94B
- 1M return
- -7.69%
- +4.33%
- 1Y return
- +359.54%
- -27.99%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 1
- 5
- Recent ratings
- 15
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BIOA
- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- Principal Accounting Officer Barton Shane exercised 59,934 shares at a strike of $6.58 and sold $1,576,752 worth of shares (62,566 units at $25.20) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
- SEC Form 4 filed by Director Pande Vijay Satyanand
- SEC Form 4 filed by Director Hemrajani Rekha
- SEC Form 4 filed by Director Healy James
- SEC Form 4 filed by Director Enright Patrick G
- SEC Form 4 filed by Director Davidson Michael H.
- SEC Form 4 filed by Director Garnier Jean Pierre
- BioAge Labs Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S